Oregon Health & Science University
Portland, Oregon, 97239, United States
Location status: Recruiting
NCT Number: NCT06461962
The goal of PEER-Heart is to implement and assess feasibility and preliminary effectiveness of a community peer-facilitated screening for methamphetamine-associated heart failure (MAHF) and linkage to evidence-based cardiology care for people who use methamphetamine in rural areas.
Interested in participating?
Request Info18 year and older
All sexes
Interventional
Not applicable
Portland, Oregon, 97239, United States
Location status: Recruiting
Methamphetamine use has increased across the US in the midst of the opioid crisis, with rates of methamphetamine use in rural communities exceeding that in urban areas. Nationwide, methamphetamine-related hospitalizations increased 270% between 2007 and 2015, along with associated costs, lengths of stay and mortality. Methamphetamine-associated heart failure (MAHF) hospitalizations increased 12-fold over this time period; it is associated with worse symptoms (e.g. ejection fraction) and decreased adherence to guideline-directed medical therapy (GDMT) compared to heart failure not associated with methamphetamine use.
Despite the increased risk of heart failure and overdose for people who use methamphetamine in rural areas, interventions to improve engagement in cardiac screening and treatment services are underdeveloped. Multiple barriers decrease access to cardiac care in rural communities, including social determinants of health and health systems care delivery barriers. Stigma and distrust of healthcare providers, particularly in rural communities are known barriers to engaging in medical care-COVID-19 has only worsened this gap for people who use drugs.
Team-based cardiology care interventions can improve outcomes for people with heart failure, including one multi-disciplinary program that focused on methamphetamine-associated heart failure MAHF. However, these interventions have been tested in urban, higher resourced settings than those typical in rural communities. Interventions for screening and linkage to care for people who use drugs in rural areas with MAHF have not been developed.
The "experiential credentialing" afforded by peer recovery support specialists ("peers") offers a unique opportunity to reach, engage, and retain non-treatment-seeking people using drugs. The PEER-Heart study extends the role of peers as trusted community health workers in rural communities to improve MAHF screening and linkage to cardiology care. Increasing evidence reports feasibility, acceptability, and effectiveness of telehealth interventions in rural communities including cardiology services and retention in substance use treatment. Virtual visits for heart failure demonstrate promise in improving follow-up care though more study is warranted to demonstrate clinical outcomes effectiveness, and ensure these interventions do not worsen existing health inequities and the rural digital divide, particularly in minoritized groups.
The PEER-Heart study aims to demonstrate feasibility of screening of MAHF and linkage to evidence-based cardiology care for people who use methamphetamine in rural areas.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Peer-facilitated referral to a local primary care provider to follow-up their screening results.
Peer-facilitated virtual consultation with cardiovascular specialist, for follow-up of their screening results. Activities may include: referral for a locally performed testing including echocardiogram and additional blood work, and transitional care management facilitated by a remote nurse care manager and the peer
Referral for a locally performed testing including echocardiogram
Transitional care management facilitated by a remote nurse care manager and the peer
Time frame: 2 months
Proportion of participants who are engaged in cardiac care at 2 months after screening.
Time frame: 2 months
Proportion of participants who complete a diagnostic echocardiogram within 2 months after randomization.
Time frame: 6 months
Proportion of eligible patients who are on any GDMT at 6 months after randomization
Contact information is provided by the study sponsor or research team.
Brian Chan, MD, MPH
CONTACT
Kellie Pertl, MPH
CONTACT
Oregon Health and Science University
Other
Acronym: PEER-Heart
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06789523
Common Mental Disorders (CMD), Methamphetamine Use
Haiphong, Hai Phong, Vietnam
View Trial DetailsNCT07584369
HIV -1 Infection, Methamphetamine Use
San Francisco, California, United States
View Trial DetailsNCT01122186
Behavior, Blood-Borne Infections
New York, United States
View Trial DetailsNCT07278583
Cardiovascular Diseases, Heart Diseases
Clermont-Ferrand, France
View Trial Details